CoChat

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

Open access
Jensen, Jacob K., Zobel, Emilie H., von Scholten, Bernt J., Rotbain Curovic, Viktor, Hansen, Tine W., Rossing, Peter, Kjaer, Andreas, Ripa, Rasmus S. · 2021 · Frontiers in Endocrinology
Cited by 47

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background: Quantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positron emission tomography (PET) with a radioactive tracer targeting activated macrophages in the vessel-wall. Methods: Thirty randomly selected participants with type 2 diabetes from the placebo-controlled trial LIRAFLAME were enrolled in this sub-study. Participants were, prior to enrollment in this sub-study, randomized to either treatment with daily liraglutide (n=15) or placebo (n=15). Both groups underwent a combined [64 Cu]Cu-DOTATATE positron emission tomography and computed tomography scan of the heart at baseline and after 26 weeks of treatment. Coronary artery uptake of [64 Cu]Cu-DOTATATE were measured as maximum standardized uptake values (SUV max); and means of the maximum values (mSUV max), both values were calculated at the level of each participant and each individual coronary-segment. Results: SUV max and mSUV max values decreased significantly in the liraglutide group both at the participant level (SUV max: p=0.013; mSUV max: p=0.004) and at the coronary-segment level (SUV max: p=0.001; mSUV max: p<0.0001). No change was observed in the placebo group neither at the participant level (SUV max: p=0.69; mSUV max: p=0.67) or at the coronary-segment level (SUV max: p=0.49; mSUV max: p=0.30). When comparing the mean change in uptake values between the two groups at both the participant level (SUV max: p=0.076; mSUV max: p=0.077) and the coronary segment level (SUV max: p=0.13; mSUV max: p=0.11) a borderline significant difference was observed. Baseline SUV max [64 Cu]Cu-DOTATATE uptake values showed a weak positive correlation with the inflammatory biomarker high-sensitivity c-reactive protein (τ =0.26, p=0.045). Conclusion: Liraglutide treatment for 26-weeks caused a significant reduction in [64 Cu]Cu-DOTATATE uptake in the coronary arteries whereas this was not seen in the placebo treated group. In addition, [64 Cu]Cu-DOTATATE PET/CT as a marker of coronary inflammation correlated with the systemic inflammation marker hs-CRP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2021.790405

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 47

Metadata

Authors
Jensen, J. K., Zobel, E. H., von Scholten, B. J., Rotbain Curovic, V., Hansen, T. W., Rossing, P., Kjaer, A., & Ripa, R. S.
Venue
Frontiers in Endocrinology
Published
2021-11-30
Volume
12
Pages
790405-790405
ISSN
1664-2392 (ISSN-L)
OpenAlex
W3215890590
Cited by
47
References
13
FWCI
4.36
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. https://app.cochat.ai/papers/10.3389/fendo.2021.790405
The paper
Jensen, J. K., Zobel, E. H., von Scholten, B. J., Rotbain Curovic, V., Hansen, T. W., Rossing, P., Kjaer, A., & Ripa, R. S. (2021). Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.790405

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.